Barclays PLC Has $98,000 Holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Barclays PLC lessened its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 91.3% in the third quarter, Holdings Channel reports. The firm owned 11,942 shares of the company’s stock after selling 125,931 shares during the quarter. Barclays PLC’s holdings in Ginkgo Bioworks were worth $98,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Wealth Strategies LLC. acquired a new position in Ginkgo Bioworks in the second quarter valued at about $41,000. PDT Partners LLC acquired a new position in Ginkgo Bioworks in the third quarter valued at about $1,199,000. Erste Asset Management GmbH acquired a new position in Ginkgo Bioworks in the third quarter valued at about $4,075,000. Jacobs Levy Equity Management Inc. acquired a new position in Ginkgo Bioworks in the third quarter valued at about $2,282,000. Finally, Benjamin F. Edwards & Company Inc. raised its stake in Ginkgo Bioworks by 1,606.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 234,836 shares of the company’s stock valued at $79,000 after purchasing an additional 221,078 shares in the last quarter. Institutional investors and hedge funds own 78.63% of the company’s stock.

Ginkgo Bioworks Stock Performance

Shares of NYSE DNA opened at $11.08 on Thursday. The firm has a market capitalization of $636.87 million, a P/E ratio of -0.85 and a beta of 1.09. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $5.26 and a 12 month high of $64.40. The business’s 50-day simple moving average is $8.99.

Analyst Upgrades and Downgrades

Separately, TD Cowen boosted their target price on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, September 20th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Ginkgo Bioworks currently has a consensus rating of “Hold” and a consensus target price of $4.58.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.